01866nam a22003257a 4500
201229s20202020 xxu||||| |||| 00| 0 eng d
0736-8046
10.1111/pde.14404 [doi]
Ovid MEDLINE(R)
33099783
Topical rapamycin for acanthosis nigricans in the Fitzpatrick IV/V adolescent population.
Pediatric Dermatology. 2020 Oct 24
Pediatr Dermatol. 2020 Oct 24
Pediatric dermatology
2020
FY2021
aheadofprint
2020-12-29
Dermatologically, FGFR3 mutations can lead to acanthosis nigricans (AN), epidermal nevi, and seborrheic keratosis. A recent case report found that topical rapamycin (sirolimus) can improve FGFR3-induced epidermal nevi with AN features in children, specifically with Fitzpatrick skin type (FST) I/II, and we would like to expand these findings to skin plaques with extensive AN-like features in the FST IV/V adolescent population. An 18-year-old female with FST IV/V and FGFR3-induced hypochondroplasia presented to our clinic with extensive AN-like plaques. Significant improvement with lightening and thinning of the plaques was observed after applying 1% topical rapamycin cream twice daily. Topical rapamycin should be considered as a treatment option for AN, particularly in FST IV/V adolescents with FGFR3-induced AN. Copyright (c) 2020 Wiley Periodicals LLC.
English
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Dermatology
Journal Article
DeKlotz, Cynthia
Todd, Sarah P
Coerdt KM, DeKlotz CMC, Todd SP
https://dx.doi.org/10.1111/pde.14404
https://dx.doi.org/10.1111/pde.14404
ART
Article
0
0
0
0
Article
authcat
authcat
2020-12-29
0
33099783
33099783
2020-12-29
2020-12-29
ART
5865
5865